Spago Nanomedical AB (SPAGO) - Net Assets

Latest as of December 2025: Skr30.75 Million SEK ≈ $3.31 Million USD

Based on the latest financial reports, Spago Nanomedical AB (SPAGO) has net assets worth Skr30.75 Million SEK (≈ $3.31 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr36.68 Million ≈ $3.95 Million USD) and total liabilities (Skr5.94 Million ≈ $638.92K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Spago Nanomedical AB to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr30.75 Million
% of Total Assets	83.82%
Annual Growth Rate	6.43%
5-Year Change	-83.36%
10-Year Change	-57.21%
Growth Volatility	64.74

Spago Nanomedical AB - Net Assets Trend (2011–2025)

This chart illustrates how Spago Nanomedical AB's net assets have evolved over time, based on quarterly financial data. Also explore Spago Nanomedical AB assets under control for the complete picture of this company's asset base.

Annual Net Assets for Spago Nanomedical AB (2011–2025)

The table below shows the annual net assets of Spago Nanomedical AB from 2011 to 2025. For live valuation and market cap data, see market value of Spago Nanomedical AB.

Year	Net Assets	Change
2025-12-31	Skr30.75 Million ≈ $3.31 Million	-7.49%
2024-12-31	Skr33.23 Million ≈ $3.58 Million	-19.56%
2023-12-31	Skr41.32 Million ≈ $4.45 Million	-79.04%
2022-12-31	Skr197.16 Million ≈ $21.22 Million	+6.68%
2021-12-31	Skr184.81 Million ≈ $19.89 Million	+15.74%
2020-12-31	Skr159.67 Million ≈ $17.18 Million	+16.02%
2019-12-31	Skr137.63 Million ≈ $14.81 Million	+12.61%
2018-12-31	Skr122.22 Million ≈ $13.15 Million	+13.40%
2017-12-31	Skr107.78 Million ≈ $11.60 Million	+50.02%
2016-12-31	Skr71.84 Million ≈ $7.73 Million	+9.84%
2015-12-31	Skr65.41 Million ≈ $7.04 Million	+16.69%
2014-12-31	Skr56.05 Million ≈ $6.03 Million	+46.82%
2013-12-31	Skr38.18 Million ≈ $4.11 Million	-9.64%
2012-12-31	Skr42.25 Million ≈ $4.55 Million	+228.96%
2011-12-31	Skr12.84 Million ≈ $1.38 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Spago Nanomedical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 71500000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	Skr6.62 Million	21.52%
Other Comprehensive Income	Skr-384.00K	-1.25%
Other Components	Skr24.51 Million	79.73%
Total Equity	Skr30.75 Million	100.00%

Spago Nanomedical AB Competitors by Market Cap

The table below lists competitors of Spago Nanomedical AB ranked by their market capitalization.

Company	Market Cap
Ace Digital AS OL:ACED	$8.48 Million
National Plastic Co Ltd Preferred KO:004255	$8.48 Million
GENINCODE PLC LS -01 F:9PL	$8.48 Million
Media Lab SpA PA:MLLAB	$8.48 Million
Truscreen Group Ltd AU:TRU	$8.46 Million
Sky Quarry Inc NASDAQ:SKYQ	$8.46 Million
Ho Hup Construction Company KLSE:5169	$8.46 Million
Noble Mineral Exploration Inc V:NOB	$8.46 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Spago Nanomedical AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 33,235,000 to 30,746,000, a change of -2,489,000 (-7.5%).
Net loss of 26,554,000 reduced equity.
Other comprehensive income increased equity by 251,966,000.
Other factors decreased equity by 227,901,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr-26.55 Million	-86.37%
Other Comprehensive Income	Skr251.97 Million	+819.51%
Other Changes	Skr-227.90 Million	-741.24%
Total Change	Skr-	-7.49%

Book Value vs Market Value Analysis

This analysis compares Spago Nanomedical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.45x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 0.00x to 1.45x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2011-12-31	Skr27.37	Skr0.12	x
2012-12-31	Skr5.02	Skr0.12	x
2013-12-31	Skr4.53	Skr0.12	x
2014-12-31	Skr5.13	Skr0.12	x
2015-12-31	Skr4.88	Skr0.12	x
2016-12-31	Skr3.93	Skr0.12	x
2017-12-31	Skr4.74	Skr0.12	x
2018-12-31	Skr2.77	Skr0.12	x
2019-12-31	Skr3.06	Skr0.12	x
2020-12-31	Skr2.75	Skr0.12	x
2021-12-31	Skr2.21	Skr0.12	x
2022-12-31	Skr1.04	Skr0.12	x
2023-12-31	Skr0.21	Skr0.12	x
2024-12-31	Skr0.11	Skr0.12	x
2025-12-31	Skr0.08	Skr0.12	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Spago Nanomedical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -86.37%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -6076.43%
• Asset Turnover: 0.01x
• Equity Multiplier: 1.19x
Recent ROE (-86.37%) is below the historical average (-29.00%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	-5.57%	-72.88%	0.04x	1.97x	Skr-2.00 Million
2012	-10.92%	-2078.83%	0.00x	1.27x	Skr-8.84 Million
2013	-14.08%	-2286.84%	0.00x	1.56x	Skr-8.92 Million
2014	-11.65%	-11353.70%	0.00x	1.44x	Skr-11.39 Million
2015	-10.39%	-90.37%	0.10x	1.14x	Skr-13.33 Million
2016	-10.49%	-13000.00%	0.00x	1.11x	Skr-14.72 Million
2017	-8.77%	-20121.28%	0.00x	1.04x	Skr-20.23 Million
2018	-9.08%	-37.42%	0.23x	1.03x	Skr-23.31 Million
2019	-14.74%	-67600.00%	0.00x	1.02x	Skr-34.04 Million
2020	-11.84%	-5527.19%	0.00x	1.02x	Skr-34.87 Million
2021	-21.14%	-5920.45%	0.00x	1.04x	Skr-57.56 Million
2022	-19.94%	-3729.51%	0.01x	1.04x	Skr-59.02 Million
2023	-102.19%	-3509.81%	0.02x	1.28x	Skr-46.35 Million
2024	-97.82%	-1701.15%	0.05x	1.19x	Skr-35.83 Million
2025	-86.37%	-6076.43%	0.01x	1.19x	Skr-29.63 Million

Industry Comparison

This section compares Spago Nanomedical AB's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $165,054,194
Average return on equity (ROE) among peers: -81.86%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Spago Nanomedical AB (SPAGO)	Skr30.75 Million	-5.57%	0.19x	$8.47 Million
2cureX AB (2CUREX)	$74.34 Million	-25.47%	0.06x	$4.90 Million
Ascelia Pharma AB (publ) (ACE)	$74.33 Million	-147.03%	0.17x	$40.96 Million
AcouSort AB (ACOU)	$15.58 Million	-57.51%	0.12x	$8.97 Million
Active Biotech AB (ACTI)	$188.64 Million	-118.73%	1.64x	$17.19 Million
Alzinova AB (ALZ)	$20.63 Million	-16.51%	0.08x	$4.97 Million
AlzeCure Pharma (ALZCUR)	$182.01 Million	-28.02%	0.03x	$18.18 Million
Annexin Pharmaceuticals AB (ANNX)	$18.81 Million	-234.16%	0.42x	$11.24 Million
Alligator Bioscience AB (ATORX)	$68.52 Million	-112.06%	0.43x	$14.33 Million
BioInvent International AB (BINV)	$219.00 Million	-63.86%	0.22x	$155.44 Million
BioArctic AB (publ) (BIOA-B)	$788.68 Million	-15.19%	0.14x	$2.59 Billion

About Spago Nanomedical AB

ST:SPAGO Sweden Biotechnology

Market Cap

$8.47 Million

Skr78.73 Million SEK

Market Cap Rank

#27272 Global

#600 in Sweden

Share Price

Skr0.12

Change (1 day)

+5.78%

52-Week Range

Skr0.09 - Skr0.40

All Time High

Skr19.04